Asset Details
Do you wish to reserve the book?
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome
Do you wish to request the book?
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome
2009
Overview
Hepatic complications of transplant are a common cause of mortality. Although mild elevations of serum aminotransferase enzymes (aspartate and alanine (AST, ALT)) do not carry an adverse prognosis, this is not the case with severe hepatocellular injury. We reviewed 6225 consecutive recipients to determine the incidence and outcomes of severe hepatocellular injury (AST >1500 U/l) before day 100, which occurred in 88 patients. Causes were sinusoidal obstruction syndrome (SOS) (
n
=46), hypoxic hepatitis (
n
=33), varicella zoster virus (VZV) hepatitis (
n
=4), drug-liver injury (
n
=2) and unknown (
n
=3). The incidence declined from 1.9% in the 1990s to 1.1% recently (owing to a fivefold decline in SOS and disappearance of VZV hepatitis). In hypoxic hepatitis, peak serum AST was 3545 U/l (range, 1380–25 246) within days of shock or prolonged hypoxemia; case fatality rate was 88%. In SOS, AST increases occurred 2–6 weeks after diagnosis; peak AST was 2252 U/l (range, 1437–8281); case fatality rate was 76%, with only serum bilirubin able to distinguish survivors (2.7 vs 11.3 mg/100 ml,
P
=0.0009). We conclude that circulatory insults (sinusoidal injury, hypotension and hypoxemia), and not infection, are the most common cause of severe hepatocellular injury, the frequency of which has declined because of a falling incidence of SOS and VZV hepatitis.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Alanine
/ Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
/ Biological and medical sciences
/ Bone marrow, stem cells transplantation. Graft versus host reaction
/ Child
/ Complications and side effects
/ Etiology
/ Female
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Hematopoietic Stem Cell Transplantation - mortality
/ Hepatic Insufficiency - epidemiology
/ Hepatic Insufficiency - etiology
/ Hepatic Insufficiency - mortality
/ Hepatic Insufficiency - therapy
/ Hepatic Veno-Occlusive Disease - complications
/ Humans
/ Hypoxia
/ Injuries
/ Male
/ Medicine
/ Opportunistic Infections - complications
/ Transfusions. Complications. Transfusion reactions. Cell and gene therapy
/ Viruses
